|

FOLFOX Clinical Trials

17 actively recruiting trials across 10 locations

No change since May 2026

Also known as: OxMdG, Oxaliplatin de Gramont

Pipeline

Phase 1: 9Phase 2: 3Phase 3: 3Phase 2/3: 2

Top Sponsors

  • Incyte Corporation3
  • TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)2
  • Celyad Oncology SA2
  • Bristol-Myers Squibb2
  • Sun Yat-sen University1

Indications

  • Cancer17
  • Unresectable Metastatic Colorectal Cancer3
  • Lung Cancer3
  • CRC (Colorectal Cancer)2
  • Solid Tumors2

Other3 trials

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
Phase 2
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
Phase 3
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Phase 2

Los Angeles, California3 trials

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

The Angeles Clinic and Research Institute

Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer

The Angeles Clinic and Research Institute - West Los Angeles Office

Phase 1
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2

Phoenix, Arizona2 trials

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital

Phase 1
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Local Institution - 0284

Phase 2/3

Tucson, Arizona2 trials

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0428

Phase 2/3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GSK Investigational Site

Phase 3

Birmingham, Alabama1 trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1

Chandler, Arizona1 trial

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Ironwood Cancer & Research Centers

Phase 3

Duarte, California1 trial

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 1

Aurora, Colorado1 trial

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

University of Colorado Denver Anschultz Medical Campus

Phase 1

Jacksonville, Florida1 trial

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Mayo Clinic

Phase 1

Tampa, Florida1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Moffit Cancer Center

Phase 1

Milwaukee, Wisconsin1 trial

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Froedtert & the Medical College of Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.